GlassScriptPhysician profile
Alan F Kenney
NPI 1922033612
$19,210.79
in general payments reported to CMS, 2019-2025
65 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,024 · 2020: $2,576 · 2021: $4,501 · 2022: $2,548 · 2023: $2,488 · 2024: $2,212 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,562.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,914.05 | 2019-2025 | Jardiance, Spiriva Respimat |
| Novo Nordisk INC | $1,885.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,757.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,510.90 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $1,268.35 | 2021 | |
| Pfizer INC. | $1,194.24 | 2019-2025 | |
| Lilly USA, LLC | $1,105.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $871.96 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $852.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $746.85 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbvie INC. | $691.02 | 2020-2025 | |
| Amarin Pharma, INC. | $558.11 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $546.54 | 2019-2023 | Xarelto |
| Dexcom, INC. | $502.89 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Esperion Therapeutics, INC. | $451.91 | 2020-2025 | Nexletol |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kenney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.